Eris Lifesciences Limited is a pharmaceutical company focused on high-growth therapeutic areas within the Indian market. The company operates primarily through two segments: Domestic Branded Formulations (DBF) and an International Business. Its domestic business is heavily concentrated on chronic and sub-chronic therapies, building a strong presence in areas like Cardiac Care, Oral Anti-Diabetics (OAD), Insulins, and Dermatology. Eris has demonstrated a clear strategy of strengthening its portfolio through both organic growth and strategic acquisitions, such as the Biocon India formulations business, which significantly bolstered its position in the insulin market. The company is committed to innovation and R&D, evidenced by its in-house development and launch of new molecules like Esaxerenone for hypertension. With a manufacturing footprint that includes facilities for insulins and injectables, Eris is also focused on achieving self-sufficiency and expanding its international presence, particularly in the EU CDMO space. The company is publicly listed on the BSE and NSE in India and maintains a diverse shareholder base comprising promoters, domestic and foreign institutional investors, and the public.

Official Website: https://eris.co.in/

• Consolidated Performance (Q3 FY26):

• Revenue stood at Rs. 807 crore, marking an 11% year-over-year (YoY) growth. Excluding the Trade Generics (TGx) business, revenue grew by 13%.

• EBITDA was Rs. 282 crore, a 13% YoY increase, with the EBITDA margin improving by 62 basis points to 35%.

• Adjusted Profit After Tax (PAT) grew significantly by 38.5% YoY to Rs. 120 crore. This was driven by lower finance costs (-15%) and a reduced effective tax rate (22.5% vs. 25.2% in Q3 FY25).

• Consolidated Performance (9M FY26):

• Revenue reached Rs. 2,373 crore, an 8.4% YoY growth. Excluding TGx, the growth was 10%.

• EBITDA increased by 11% YoY to Rs. 847 crore, with the margin expanding by 77 basis points to 35.7%.

• Adjusted PAT saw a 39.3% YoY increase to Rs. 380 crore, supported by a 17% reduction in finance costs and a 207 basis point drop in the book tax rate over the nine-month period.

• Segment Performance - Domestic Branded Formulations (DBF):

• DBF revenue grew 10% YoY in both Q3 (Rs. 696 crore) and 9M (Rs. 2,106 crore).

• DBF EBITDA for Q3 was Rs. 254 crore (10% growth) with a margin of 36.5%. For 9M, EBITDA was Rs. 781 crore (12% growth) with a margin of 37.1%.

• Segment Performance - International Business:

• This segment reported its strongest quarter yet, with Q3 revenue growing 45% YoY to Rs. 111 crore.

• Q3 EBITDA for the international business grew 46% YoY to Rs. 33 crore.

• For 9M FY26, revenue was Rs. 259 crore (11% growth) with an EBITDA of Rs. 81 crore (10% growth).

• Debt Position:

• Net Debt as of December 31, 2025, was Rs. 2,270 crore.

• The Net Debt to TTM EBITDA ratio stands at 2.1x, down significantly from 3.9x as of March 31, 2024. The company is on track to achieve a ratio of less than 1.5x by December 2026.

Summary: The company delivered strong double-digit growth in consolidated revenue and EBITDA for Q3 FY26, with significant PAT expansion driven by operational efficiency, lower finance costs, and a favorable tax rate. Both domestic and international segments are contributing to this growth, and the balance sheet is strengthening through consistent debt reduction.

• Aggressive Market Share Capture in Insulins:

• Following the acquisition from Biocon, Eris has tripled its market share in RHI Cartridges by sales (from 8% to 25%) and nearly tripled it by prescriptions (from 10% to 28%) between April 2024 and December 2025.

• In the total RHI + Glargine market, valued at over Rs. 3,000 crore, the company has nearly doubled its market share from 9% to 16% in the same period. This demonstrates a superior go-to-market strategy and execution.

• In-House R&D and First-to-Market Launches:

• The company developed and launched Esaxerenone, a next-generation therapy for uncontrolled and resistant hypertension.

• This launch showcases Eris's in-house R&D capabilities and its commitment to introducing innovative, clinically superior products to the Indian market, positioning it as a leader in patient care.

• Strategic Positioning in Emerging Therapies (GLP-1):

• Eris is prepared for the launch of Semaglutide (a GLP-1 agonist), having secured a strategic partnership and established in-house form-fill-finish manufacturing capabilities.

• This positions the company to capitalize on the large and rapidly growing GLP-1 market in India, particularly given its strong existing relationships with endocrinologists and diabetologists who lead prescriptions in this segment.

Summary: Eris differentiates itself through its aggressive execution in capturing market share in key therapeutic areas like insulins, its capability to bring novel, in-house developed treatments to market, and its strategic foresight in preparing for next-generation therapies like GLP-1.

• Insulin Market Dynamics:

• The core RHI + Glargine insulin market is a significant opportunity, valued at over Rs. 3,000 crore annually. The exit of an innovator brand is creating a vacuum that Eris is successfully filling.

• The adjacent Insulin Analogues market (Aspart, Degludec, Lispro) represents a further Rs. 1,750+ crore opportunity, currently dominated by innovator brands and growing at a 3-year CAGR of 10%.

• GLP-1 Market Opportunity:

• The GLP-1 market in India is described as large and fast-emerging.

• Endocrinologists and Diabetologists, a core prescriber base for Eris, dominate this segment with a 68% prescription share. Recent clinical trials demonstrating Semaglutide's cardiovascular benefits are particularly relevant for the Indian population, suggesting strong potential uptake.

• Therapy Area Growth Trends (vs. CVM - Chronic & Vitamin Market):

• Insulins: Eris's growth (50.4% in Dec-25) is exponentially ahead of the market, which is impacted by the innovator's exit.

• Cardiac Care: After a period of underperformance, Eris's portfolio is now catching up with market growth rates.

• Dermatology: Eris continues to consistently outperform the market in this segment.

• Oral Anti-Diabetics (OAD): Eris is currently lagging the market due to a specific product ban, which is expected to be a short-to-medium term headwind.

Summary: The company operates in large, growing chronic therapy markets with clear opportunities to gain share from innovator brands, particularly in Insulins and upcoming GLP-1s. While facing a temporary setback in its OAD portfolio, its performance in other core areas like Insulins and Dermatology remains robust.

• Core Domestic Portfolio Growth:

• The company has decided to discontinue a basket of non-core, low-growth, low-profitability brands, which will impact FY27 DBF revenue by ~2%.

• Excluding these brands, the core DBF portfolio grew at a strong 12% in Q3 and 9M FY26 and is projected to deliver 14% growth for the full fiscal year FY26.

• International Business Growth Trajectory:

• The International Business delivered robust 45% YoY revenue growth in Q3 FY26.

• The company has strong visibility for this segment to be a breakout performer in FY27, guiding for revenue of Rs. 550-600 crore, a significant jump from the FY26 expected revenue of Rs. 370-375 crore.

• FY26 Consolidated Guidance:

• The company projects full-year FY26 consolidated revenue of ~Rs. 3,200 crore, representing 10% YoY growth (12% excluding TGx).

• FY26 consolidated EBITDA is expected to be ~Rs. 1,150 crore, a 14% YoY growth (15% excluding TGx).

Summary: Growth is being driven by a strong core domestic portfolio and a rapidly accelerating international business, with clear guidance indicating continued double-digit expansion at the consolidated level for the full fiscal year.

• Insulin Dominance:

• The primary opportunity is to achieve the stated objective of 25% market share in the Rs. 3,000+ crore RHI + Glargine market.

• Further expansion into the Rs. 1,750+ crore insulin analogues market with planned launches of Aspart, Aspart Mix, and Degludec in FY27.

• Hypertension Market Penetration:

• The launch of Esaxerenone provides a new growth driver in the hypertension market. Its clinically proven superiority over Eplerenone in reducing blood pressure and providing organ protection creates a strong value proposition for cardiologists.

• GLP-1 Launch:

• The upcoming launch of Semaglutide positions Eris to capture a significant share of the fast-emerging GLP-1 market, leveraging its strong prescriber relationships and manufacturing self-sufficiency.

• International Business Expansion:

• The EU-CDMO order book is ramping up rapidly, projected to exceed Rs. 1,000 crore by the end of Q3 FY27.

• Additional growth will come from corticosteroids, new product approvals in Latin America, potential Semaglutide CMO contracts, and exports from its AMD site. The business is on track to achieve Rs. 1,000 crore in revenue by 2029/2030.

Summary: Eris has multiple, well-defined growth opportunities across its domestic and international businesses, including gaining leadership in the insulin market, launching new blockbuster drugs, and rapidly scaling its high-margin international CDMO operations.

• Manufacturing Readiness:

• Insulins (Bhopal): In-house manufacturing of RHI Vials started in Aug-25, and Glargine Vials in Feb-26. Commercial manufacturing for Cartridges is on track to begin in Q2-FY27.

• GLP-1 (AMD Site): Form-fill-finish process validation for Semaglutide is complete. The company has adequate manufacturing capacity and the ability to double it with minimal investment.

• International: A third injectable unit is set to be commissioned in FY28 to support the growth of the international business.

• Capital Expenditure:

• Total capex guidance for the period FY26-FY28 is maintained at Rs. 750-800 crore.

• Capex in Q3 FY26 was Rs. 78 crore, bringing the 9M FY26 total to Rs. 195 crore. This investment is largely directed towards building out Insulin/GLP-1 and General Injectables capabilities.

Summary: The company is making strategic capital investments to build in-house manufacturing capabilities for key future growth drivers like insulins and GLP-1s, ensuring supply chain control and margin benefits, with clear plans for further capacity expansion.

• Portfolio Optimization: The company will discontinue non-core/tail-end brands, a move expected to improve absolute operating profits and margins starting in FY27.

• Achieve Insulin Leadership: The primary strategic goal is to secure a 25% market share in the core RHI + Glargine insulin market and successfully launch new insulin analogues in FY27.

• Scale International Business: The plan is to aggressively grow the international business, targeting Rs. 550-600 crore in revenue for FY27 and Rs. 1,000 crore by 2029/2030, driven significantly by the EU-CDMO pipeline.

• Deleveraging: A key financial goal is to continue reducing debt, with a clear target of bringing the Net Debt to TTM EBITDA ratio below 1.5x by December 2026.

• New Launches: Successfully commercialize the recent launch of Esaxerenone and prepare for the imminent launch of Semaglutide to drive growth in the Cardiac and Diabetes portfolios.

Summary: Eris's future plans are centered on a clear strategy of optimizing its domestic portfolio, achieving market leadership in insulins, rapidly scaling its international operations, and strengthening its balance sheet through disciplined debt reduction.

• Consolidated Margin Expansion:

• Consolidated EBITDA margin for Q3 FY26 was 35%, up 62 bps YoY. The 9M FY26 margin was 35.7%, up 77 bps YoY.

• The company projects a full-year FY26 consolidated EBITDA margin of ~36%, an improvement from 35% in FY25.

• Domestic Branded Formulations (DBF) Margin:

• The Q3 FY26 DBF EBITDA margin was strong at 36.5%.

• The core DBF portfolio (excluding the tail-end brands being discontinued) is projected to operate at a higher EBITDA margin of ~39%.

• International Business Margin:

• The EBITDA margin for this segment was 30% in Q3 and 31% for 9M FY26.

• This represents a temporary compression compared to FY25 due to significant upfront investments in personnel and EU CDMO capabilities, the full benefits of which are expected from FY27 onwards.

Summary: The company is demonstrating consistent margin expansion at the consolidated level, with the highly profitable core domestic business driving performance and the international business poised for margin improvement after a period of strategic investment.

• Insulin Market: Eris is directly competing with and taking significant market share from the "innovator brand." Its ability to triple its market share in RHI Cartridges in just over a year indicates a highly effective competitive strategy.

• Therapy Area Benchmarking:

• The company's performance is benchmarked against the Chronic & Vitamin Market (CVM).

• Eris is outperforming the market substantially in Insulins and consistently in Dermatology.

• It is now matching market growth in Cardiac Care after previously lagging, demonstrating a successful turnaround in this therapy.

Summary: Eris is effectively competing against established innovator brands, particularly in the insulin segment where it is rapidly gaining share, and is outperforming the broader market in several of its core therapeutic areas.

• Regulatory Impact on OAD Portfolio:

• The company's Oral Anti-Diabetic (OAD) portfolio has been negatively impacted by a ban on Fixed-Dose Combinations (FDCs) affecting important SKUs like Glimisave MV and Triglimisave HS.

• Management expects growth in this specific sub-segment to lag the market for the next 2-3 quarters as a direct result of this ban.

Summary: The primary identified risk is a regulatory headwind impacting a portion of the diabetes portfolio, which is expected to temporarily suppress growth in that specific area.

• Portfolio Rationalization: The company has made a strategic decision to discontinue a basket of non-core/tail-end brands. This move, while impacting headline revenue by ~2% in FY27, is designed to enhance focus, improve absolute operating profit, and expand margins.

• Exceptional Item: An exceptional item of Rs. 17 crore was recorded in Q3 FY26 due to accounting adjustments required by the New Labour Code.

• Shareholding Structure: As of December 2025, promoters hold a 54.85% stake in the company. Domestic Institutional Investors (DIIs) hold 20.32% and Foreign Portfolio Investors (FPIs) hold 15.64%, indicating strong institutional confidence.

Summary: The company is actively refining its product portfolio for better profitability and navigating accounting changes, all while maintaining a stable and institutionally-backed shareholding structure.